GWM
TEVA icon

Graybill Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Graybill Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-303
Closed -$4.66K – 167
2025
Q1 		$4.66K Buy
+303
New +$5.41K ﹤0.01% 169

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Graybill Wealth Management's TEVA Position: Q2 2025 in Review

Graybill Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 303 shares — an estimated $4.66K sold.

Graybill Wealth Management first reported a position in TEVA in Q1 2025 and held it in 1 quarter. The position peaked at $4.66K in Q1 2025. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Graybill Wealth Management reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Graybill Wealth Management sold 303 Teva Pharmaceuticals shares in Q2 2025, an estimated $4.66K.
  • Graybill Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Graybill Wealth Management's Teva Pharmaceuticals position peaked at $4.66K in Q1 2025.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Graybill Wealth Management's 13F filing for Q2 2025, filed 31 Jul 2025.